What is the recommended treatment for a patient with confirmed genital Chlamydia trachomatis infection?

Treatment of Confirmed Chlamydia

For uncomplicated genital chlamydia in non-pregnant adults, doxycycline 100 mg orally twice daily for 7 days is the preferred first-line treatment, achieving 95-98% cure rates, with azithromycin 1 g orally as a single dose reserved for situations where compliance with a 7-day regimen is uncertain. 1, 2

First-Line Treatment Selection

The choice between doxycycline and azithromycin depends on specific clinical circumstances:

Doxycycline 100 mg twice daily for 7 days

• Preferred for most patients because it achieves 98% cure rates, costs less than azithromycin, and demonstrates superior efficacy for rectal chlamydia (94-100% cure vs. 79-87% with azithromycin). 1, 3
• The 2025 European guideline explicitly recommends doxycycline over single-dose azithromycin regimens as first-line therapy. 2
• A delayed-release formulation (200 mg once daily for 7 days) is FDA-approved and equally effective (95.5% cure) with better tolerability—nausea in 13% vs. 21% and vomiting in 8% vs. 12% compared to standard dosing. 1
• Absolutely contraindicated in pregnancy; use azithromycin or amoxicillin instead. 1

Azithromycin 1 g orally as a single dose

• Achieves 97% cure rates and is preferred when compliance with a 7-day regimen is questionable, particularly in populations with erratic health-care-seeking behavior (e.g., homeless individuals, adolescents). 1, 4
• Allows directly observed therapy, eliminating adherence concerns. 1
• Preferred during pregnancy as the safest and most effective option. 1
• More expensive than doxycycline without superior efficacy at genital sites. 1, 5

Alternative Regimens (When First-Line Agents Cannot Be Used)

If both azithromycin and doxycycline are contraindicated or not tolerated:

• Levofloxacin 500 mg orally once daily for 7 days – achieves 88-94% cure rates (inferior to first-line agents at 97-98%) and lacks clinical trial validation for chlamydia; reserve for documented allergy or severe intolerance to both first-line therapies. 1
• Ofloxacin 300 mg orally twice daily for 7 days – similar efficacy to first-line agents but more expensive with no compliance advantage over doxycycline. 1, 5
• Erythromycin base 500 mg orally four times daily for 7 days or erythromycin ethylsuccinate 800 mg orally four times daily for 7 days – less efficacious than azithromycin or doxycycline; gastrointestinal side effects frequently cause poor compliance. 1
• All fluoroquinolones (ofloxacin, levofloxacin) are absolutely contraindicated in pregnancy. 1

Treatment During Pregnancy

• Azithromycin 1 g orally as a single dose is the preferred treatment. 1
• Amoxicillin 500 mg orally three times daily for 7 days is an acceptable alternative with comparable cure rates (≈58% vs. ≈64%, not statistically different). 1
• If azithromycin and amoxicillin cannot be used, erythromycin base 500 mg four times daily for 7 days or erythromycin ethylsuccinate 800 mg four times daily for 7 days are secondary options. 1
• Erythromycin estolate is contraindicated in pregnancy due to drug-related hepatotoxicity. 1
• Mandatory test-of-cure 3-4 weeks after completing therapy (preferably by culture) because alternative regimens have lower efficacy and higher rates of gastrointestinal side effects leading to non-compliance. 1

Pediatric Dosing

• Children ≥8 years weighing >45 kg: Azithromycin 1 g orally as a single dose or doxycycline 100 mg orally twice daily for 7 days. 1
• Children <45 kg: Erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses daily for 14 days. 1
• Neonates with chlamydial conjunctivitis or pneumonia (1-3 months): Erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses daily for 14 days (≈80% effective; may require a second course). 1

Sexual Abstinence and Partner Management

• Patients must abstain from all sexual intercourse for 7 days after initiating treatment (regardless of regimen) and until all sex partners have completed treatment. 1
• All sex partners from the preceding 60 days must be evaluated, tested, and treated empirically with the same first-line regimen, even if asymptomatic. 1
• If the most recent sexual contact occurred >60 days before diagnosis, that partner should still receive empiric treatment. 1
• Delaying partner treatment while awaiting test results increases complications and ongoing transmission; the adverse effects of treating an uninfected partner are primarily psychosocial, while antibiotics for chlamydia have mild and uncommon side effects. 1
• Failing to treat sex partners leads to reinfection in up to 20% of cases. 1

Concurrent Gonorrhea Testing and Treatment

• Perform NAAT testing for gonorrhea at the initial visit because coinfection rates are 20-40% in populations with high gonorrhea prevalence. 1
• If gonorrhea is confirmed or prevalence exceeds 5% in the patient population, treat concurrently with ceftriaxone 250 mg IM single dose PLUS azithromycin 1 g orally single dose. 1
• In high-prevalence settings (e.g., many STD clinics), treat presumptively for both infections without waiting for test results. 1

Additional STI Screening

• All patients diagnosed with chlamydia should be tested for syphilis and HIV at the initial visit. 1
• Consider HPV vaccination referral, smoking cessation counseling, and influenza vaccine offer. 1

Follow-Up and Test-of-Cure

• Test-of-cure is NOT recommended for non-pregnant patients treated with recommended regimens (azithromycin or doxycycline) unless therapeutic compliance is questionable, symptoms persist, or reinfection is suspected. 1, 4
• Testing before 3 weeks post-treatment is unreliable because nucleic acid amplification tests can yield false-positive results from dead organisms that persist after successful treatment. 1
• All women should be retested approximately 3 months after treatment to screen for reinfection (not test-of-cure), regardless of whether partners were reportedly treated, because reinfection rates reach up to 39% in some adolescent populations. 1, 6
• Repeat infections carry an elevated risk for pelvic inflammatory disease and other complications compared to initial infection. 1, 6
• Men may also benefit from retesting at approximately 3 months, though evidence is more limited. 1

Medication Dispensing Best Practices

• Medications should be dispensed on-site when possible, with the first dose directly observed to maximize compliance. 1
• For patients with uncertain compliance or unpredictable follow-up, administer azithromycin 1 g as a single dose under direct observation. 1

Management of Persistent or Recurrent Symptoms

• Do NOT retreat based on symptoms alone; require objective evidence of urethral inflammation (≥5 WBC per high-power field) before considering additional therapy. 1
• If symptoms persist after completing treatment, consider testing for Mycoplasma genitalium using NAAT on first-void urine or urethral swab, as this organism causes doxycycline-resistant urethritis. 1
• For confirmed M. genitalium infection, moxifloxacin 400 mg orally once daily for 7 days is highly effective, particularly for macrolide-resistant strains. 1
• If treatment failure is due to non-adherence or re-exposure to an untreated partner, retreat with the same first-line regimen. 1

Critical Pitfalls to Avoid

• Do NOT use combination antifungal-corticosteroid preparations without definitive diagnosis, as steroids worsen infections. 7
• Do NOT wait for test results if compliance with return visit is uncertain in high-prevalence populations—treat presumptively. 1
• Do NOT assume partners were treated—directly verify or use expedited partner therapy strategies. 1
• Do NOT perform test-of-cure in asymptomatic non-pregnant patients treated with recommended regimens, as this wastes resources and may yield false-positive results. 1
• Do NOT use erythromycin estolate in pregnancy due to hepatotoxicity risk. 1
• Do NOT use doxycycline, ofloxacin, levofloxacin, or any fluoroquinolones in pregnancy due to teratogenic potential. 1